title: Dendritic cell-based immunotherapy in mesothelioma.
abstract: Mesothelioma is a rare thoracic malignancy with a dismal prognosis. Current treatment options are scarce and clinical outcomes are rather disappointing. Due to the immunogenic nature of mesothelioma, several studies have investigated immunotherapeutic strategies to improve the prognosis of patients with mesothelioma. In the last decade, progress in knowledge of the modulation of the immune system to attack the tumor has been remarkable, but the optimal strategy for immunotherapy has yet to be unraveled. Because of their potent antigen-presenting capacity, dendritic cells are acknowledged as a promising agent in immunotherapeutic approaches in a number of malignancies. This review gives an update and provides a future perspective in which immunotherapy may improve the outcome of mesothelioma therapy.
authors.affiliation: Department of Pulmonary Medicine, Erasmus MC, SV-125, PO-Box 2040, 3000 CA Rotterdam, The Netherlands. r.cornelissen@erasmusmc.nl
authors.forename: Robin
authors.initials: R
authors.lastname: Cornelissen
authors.forename: Lysanne A
authors.initials: LA
authors.lastname: Lievense
authors.forename: Marlies E
authors.initials: ME
authors.lastname: Heuvers
authors.forename: Alexander P
authors.initials: AP
authors.lastname: Maat
authors.forename: Rudi W
authors.initials: RW
authors.lastname: Hendriks
authors.forename: Henk C
authors.initials: HC
authors.lastname: Hoogsteden
authors.forename: Joost P
authors.initials: JP
authors.lastname: Hegmans
authors.forename: Joachim G
authors.initials: JG
authors.lastname: Aerts
mesh_terms: D000818:Animals; D003713:Dendritic Cells / Q000276:immunology* / Q000637:transplantation*; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D008654:Mesothelioma / Q000276:immunology* / Q000628:therapy*